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Available online 27 August 2011Abstract Endothelial cells (EC) are important in vasculogenesis and organogenesis during development and in the pathogen-
esis of cancer and cardiovascular diseases. However, few EC specification factors are known and primary EC production remains
inefficient. Based on recent studies implicating endoglin (Eng) in early vascular development and angiogenesis, we hypothe-
sized that Engmay be an EC specification gene. Mouse embryonic stem cells (ESC) were treated with recombinant Eng or a plas-
mid expressing the Eng ORF, and differentiated in the presence or absence of bone morphogenic protein 4 (BMP4). Expression
of the mesoderm and EC marker genes, the known mediators of EC specification and their downstream targets was monitored
by quantitative PCR, western blot, immunocytochemistry, and flow cytometry. Functionality of the differentiated EC was
assessed by in vitro angiogenesis assay and the induction of Icam1 expression in response to TNF-α treatment. Both recombi-
nant Eng and forced Eng expression increased the number of functional EC expressing the EC marker genes VE-cadherin,
vWF, and Tie2, and enhanced the effect of BMP4. The Eng-induced EC differentiation was independent of known mediators
of EC specification such as Indian Hedgehog (IHH) and BMP4 or of BMP4/Smad1/5/8 signaling. These studies suggest that Eng
is a novel EC specification gene.
© 2011 Elsevier B.V. All rights reserved.Introduction
Endothelial cells (EC) are key mediators of vasculogenesis
during development and angiogenesis during the pathogene-
sis of ischemic cardiovascular diseases and cancer (Poole et
al., 2001; Landmesser et al., 2004; Willerson and Ridker,
2004; Elzarrad et al., 2009). They also play a central role
in general organogenesis (Levenberg et al., 2007), making
them an important tool for tissue engineering and for study-
ing the mechanisms involved in the pathogenesis of different
forms of vascular diseases, cancer and diabetes.⁎ Corresponding author. Fax: +1 404 752 1042.
E-mail addresses: sujoy@ivri.res.in (S.K. Dhara),
mbacanamwo@msm.edu (M. Bacanamwo).
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doi:10.1016/j.scr.2011.08.006Embryonic stem cells (ESC) are considered to be a better
source for EC than other EC progenitors due to their prolifera-
tive and self renewal capacity and their ability to differentiate
into endothelial progenitors and fully differentiated EC when
directed by the appropriate set of environmental factors.
Therefore understanding the molecular mechanisms of endo-
thelial differentiation from ESC is essential for tissue engineer-
ing and therapeutic applications. However, EC differentiation
from progenitor cells remains inefficient (Iacobas et al.,
2010). Currently, only two different growth factors BMP4 and
IHH were found to be sufficient in inducing EC specification
from ESC (Iacobas et al., 2010) and more work is needed to un-
cover novel EC specification genes.
Eng is a transmembrane auxiliary receptor of the trans-
forming growth factor-β (TGF-β) family that is predominantly
expressed on proliferating vascular endothelial cells (Cheifetz
86 S. Banerjee et al.et al., 1992). Soluble Eng binds several specific members of
the TGF-β superfamily including TGF-β1, TGF-β3, activin,
and BMP. It also binds to types I and II TGF-β receptors and
may inhibit binding of the TGF-β family ligands to their cog-
nate TGF receptors and signaling to downstream targets such
as the Smads transcription factors. So, soluble Eng may act
by interfering with BMP4 binding to its cell surface receptors
and downstream signaling. Membrane-bound Eng may act as
a receptor for BMP4 and may enhance BMP4 signaling. Eng-de-
ficient mice die during mid-gestation due to angiogenesis and
cardiovascular defects and mutations in Eng have been linked
to hereditary hemorrhagic telangiectasia 1 (HHT1) (ten Dijke
et al., 2008) suggesting a possible role of Eng in early cardio-
vascular development, angiogenesis and vascular remodeling.
In addition, the number of EC marker-positive circulating
mono-nuclear cells in HHT1 patients, supposedly with low
Eng levels, was found to be significantly lower than that
from healthy donors (van Laake et al., 2006), again suggesting
Eng as a potential EC specification gene.
In the present study using a mouse ESC model system we
show that Eng induces a robust differentiation of ESC into
functional EC, i.e. expressing endothelial specific proteins,
capable of angiogenesis and showing a TNF-α inducible
Icam-1 expression. Eng synergizes with BMP4 in inducing EC
specification, leading to an even greater EC differentiation.Results
Recombinant Eng enhances BMP4-induced increase in
the expression of the mesodermal marker brachyury
in ESC
To begin establishing the potential role of Eng in EC specifica-
tion and define its effective concentration, we determined
the effect of various concentrations of recombinant Eng on
the expression of the mesodermal marker brachyury, in the
presence of BMP4, a factor that has been shown to be required
for mesoderm formation (Winnier et al., 1995). Recombinant
Eng enhanced BMP4-induced brachyury expression in a dose-
dependent manner, with 700 ng/mL inducing the highest bra-
chyury expression (Fig. 1A). This dose was used in subsequent
experiments.Figure 1 Recombinant Eng enhances BMP4-induced increase in the
number of cells expressing the EC markers and enhances the BMP4-in
sitometric quantification of expression of the mesodermal marker bra
with BMP4 (100 ng/mL) and various doses of recombinant Eng. (B, C)
munocytochemistry. VE-cadherin and vWF staining (green, Alexa Flu
(700 ng/mL) treatment. Nuclear counter staining was performed usin
Microscope with Olympus micro DP 70 software. The magnification
cells expressing the endothelial markers following BMP4 (100 ng/mL
was performed after six days of differentiation using FACSCalibur flo
(D). Representative plots of Tie2 positive cells. (E). Quantitative an
from the flow cytometry data. (F–G). Flow cytometric analysis of C
Tie2 double positive cells. (G). Quantitative and statistical analysis o
the flow cytometry data. Data are representative of at least three d
respectively.Recombinant Eng increases the number of cells
expressing the EC markers and enhances the BMP4-
induced increase in this cell population
To further establish the role of Eng in EC specification, we
determined the effect of recombinant Eng on the number
of cells expressing the EC marker genes VE-cadherin, vWF,
and Tie2. Immunofluorescence staining of the mature EC
markers VE-cadherin and vWF showed that recombinant
Eng increased the number of cells expressing VE-cadherin
(Fig. 1B) and vWF (Fig. 1C) relative to vehicle-treated
cells. Mouse brain endothelial cells (mBEC) were used as pos-
itive control (Fig. 1B–C) and there was no expression of VE-
cadherin and vWF detected in ESC in self-renewal media
(data not shown). The number of VE-cadherin-and vWF-
expressing cells was also increased by BMP4 treatment rela-
tive to vehicle-treated cells, and this number was further in-
creased by combining BMP4 treatment with recombinant Eng
treatment (Fig. 1B–C). McCloskey et al. (2006) reported that
VE-cadherin in the ESC-derived EC did not localize as well at
the cell–cell junctions as in the mature endothelial cells.
However, in the recombinant Eng-induced differentiation,
VE-cadherin did correctly localize in cell–cell junctions
(Fig. 1B), suggesting that these are functional EC.
Flow cytometric quantification of the proportion of cells
expressing the ECmarker Tie-2 (Kisanuki et al., 2001) revealed
that indeed, the percentage of cells expressing Tie2 was in-
creased by recombinant Eng treatment relative to vehicle-
treated cells (17.1±2.5 vs. 26.0±1.5, p≤0.01) (Fig. 1D–E).
BMP4 also increased the percentage of Tie2-positive cells rel-
ative to controls (17.1±2.5 vs. 26.4±1.3, p≤0.01), and the
percentage was further increased by combining BMP4 with re-
combinant Eng treatment (26.4±1.3 vs. 34.5±2.6, p≤0.01)
(Fig. 1D–E). About 90% of mBEC used as positive control
expressed Tie2 (Fig. 1D). Similarly flow cytometric analysis
of cells expressing both CD31 and Tie2 indicated that the per-
centage of CD31+ Tie2+ cells was increased by recombinant
Eng treatment relative to the vehicle-treated cells (7.7±0.9
vs. 23.9±1.1, p≤0.01) (Fig. 1F–G). BMP4 also increased the
proportion of CD31+ Tie2+ cells relative to the vehicle-treated
cells (7.7±0.9 vs. 15.7±1.3, p≤0.01) and the percentage was
further increased by combining BMP4 and recombinant Eng
treatment (15.7±1.3 vs. 28.3±1.2%, p≤0.01), (Fig. 1F–G).expression of the mesodermal marker brachyury, increases the
duced increase in this cell population. (A). Western blot and den-
chyury in differentiating mouse ESC after four days of treatment
. Detection of VE-cadherin- (B) and vWF (C)-positive cells by im-
or 488) was performed six days after BMP4 (100 ng/mL) and Eng
g DAPI (blue). Images were acquired using Olympus IX71 Inverted
was ×200. (D–G). Flow cytometric analysis of the percentage of
) and recombinant Eng (700 ng/mL) treatment. Flow cytometry
w cytometer and data were analyzed using FlowJo7.6 software.
d statistical analysis of the percentage of cells expressing Tie2
D31+ Tie2+ cells. (F). Representative scatter plots of CD 31 and
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Figure 1 (continued).
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for both CD31 and Tie2 (data not shown).
Forced Eng expression in ESC enhances and prolongs
the stimulatory effect of BMP4 on the expression of
mesodermal markers, increases the number of cells
expressing the EC markers and enhances the BMP4-
induced increase in this cell population
To verify the ability of the Eng expression vector to over-express
Eng in transfected mouse ESC, expression of Eng was deter-
mined 24 h and 48 h after transfection by quantitative PCR
and 24 h after transfection by immunocytochemistry. Eng was
found to be highly expressed at both mRNA and protein levels
in cells transfected with the Eng expression vector, while
there was no expression in cells treated with the empty vectors
(Fig. 2A–B). We also found that forced Eng expression resulted
in expression of both the membrane-bound and the soluble
forms of Eng (Fig. 2B).
To determine whether Eng acts at the level of mesendo-
dermal or vascular mesoderm specification or even at a
later stage, we determined the expression of mesoderm
markers during the early stage of ESC differentiation.
Fig. 2C indicates that BMP4 treatment increases the expres-
sion of the primitive streak/mesendoderm and early meso-
derm markers brachyury (Kispert and Herrmann, 1994) and
Wnt3 (Liu et al., 1999). The stimulatory effect of BMP4 on
the expression of the mesendoderm/mesoderm markers de-
clined with time but the BMP4 effect was sustained by forced
Eng expression (Fig. 2C). Forced Eng expression had no ef-
fect on mesendoderm/mesoderm formation in absence of
BMP4 (Fig. 2C).
To verify the endothelial fate of the Eng-over-expressing
mESC, cells were stained for the expression of the EC markers
VE-cadherin, vWF, and Tie2. The number of cells expressing
the EC marker genes after 6 days of differentiation was deter-
mined by immunocytochemistry and flow cytometry. Immuno-
fluorescence staining of the mature EC markers VE-cadherin
and vWF showed that forced Eng expression increased thenumber of cells expressing VE-cadherin (Fig. 2D) and vWF
(Fig. 2E) relative to vehicle-treated cells. Like in EC-differen-
tiation induced by recombinant Eng described above, VE-cad-
herin was correctly localized at the cell–cell junction
following forced Eng expression, suggesting potentially func-
tional EC. The number of VE-cadherin- and vWF-expressing
cells was also increased by BMP4 treatment relative to
empty vector-treated cells, and this number was further in-
creased by combining BMP4 treatment with forced Eng expres-
sion (Fig. 2D–E). mBEC were used as positive control (Fig. 2D–
E). Flow cytometric quantification of the proportion of cells
expressing the EC marker Tie2 confirmed that the percentage
of cells expressing Tie2 was increased by forced Eng expression
relative to empty vector-treated cells (19.3±1.0 vs. 28.0±1.2,
p≤0.01) (Fig. 2F–G). BMP4 also increased the percentage of
Tie2-positive cells relative to controls (19.3±1.0 vs. 26.0±1.3,
p≤0.01), and the percentage was further increased by combin-
ing BMP4 and forced Eng expression (26.0±1.3 vs. 35.3±1.6,
p≤0.01) (Fig. 2F–G). More than 90% of mBEC used as positive
control expressed Tie2 (Fig. 2F). Further flow cytometric analy-
sis revealed that the number of CD31 and Tie2 double positive
cells was increased by forced Eng expression relative to empty
vector-treated cells (9.9±0.6 vs. 20.7±1.4%, p≤0.01)
(Fig. 2H–I). Moreover BMP4 also increased the percentage of
CD31+ Tie2+ cells relative to the controls (9.9±0.6 vs. 15.4±
1.2, p≤0.01) (Fig. 2H–I), and the proportion was further in-
creased by combining BMP4 and forced Eng expression (15.4±
1.2 vs. 25.6±1.5%, p≤0.01%) (Fig. 2H–I). More than 90% of
mBEC used as positive control were double positive for both
CD31 and Tie2 (data not shown).Eng induces mouse ESC to differentiate into func-
tional EC
To determine if the cells resulting from the Eng-mediated dif-
ferentiation of ESC were functional EC, we determined their
angiogenesis ability by in-vitro angiogenesis assay and their
ability to increase Icam-1 expression in response to TNF-α
treatment. Cells treated with recombinant Eng were found
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cells within 6 h of the assay (Fig. 3A). BMP4-treated cells also
had more vascular-like network formation than the control,
and the effect of BMP4 was further enhanced by recombinant
Eng (Fig. 3A). Similarly, forced expression of Eng in differenti-
ating ESC resulted in relatively more vascular-like network
formation than in ESC treated with empty vector, and forced
Eng expression enhanced the BMP4-induced vascular like-net-
work formation (Fig. 3B). Because vascular-like network for-
mation was not robust in cells with forced Eng expression,
we determined the ability of differentiated cells to induce
Icam-1 expression in response to TNF-α treatment. Increased
expression of Icam-1 in response to TNF-α treatment is a char-
acteristic of mature EC and this assay has been used to mea-
sure the functionality of differentiated EC (Nourse et al.,
2010). The TNF-α-induced increase in Icam-1 expression was
increased by forced Eng expression and forced Eng expression
further increased the BMP4-induced Icam-1 expression
(Fig. 3C).
Eng effects are not mediated by either Ihh or Bmp4
To determine the molecular mechanisms mediating the Eng
effects on EC specification, we investigated the effect of
Eng on the expression of the two signaling molecules
known to be sufficient for EC specification, IHH and Bmp4
(Kelly and Hirschi, 2009). No significant differences in Ihh
or Bmp4 mRNA were detected between the control and
Eng-over-expressing cells after 24 h, 48 h and 72 h of forced
Eng expression (Fig. 4A–B).
Recombinant Eng antagonizes the BMP4-induced
increase in phospho-Smad1/5/8
To investigate the effect of recombinant Eng, cells were har-
vested 24 h after treatment with BMP4 and recombinant
Eng, and levels of phospho-Smad1/5/8 were probed by west-
ern blot. Levels of phospho-Smad1/5/8 were increased in re-
sponse to BMP4 treatment. However, the BMP4-induced
increase in phospho-Smad1/5/8 levels was decreased in the
presence of recombinant Eng (Fig. 4C).
Forced Eng expression enhances the BMP4-induced
increase in phospho-Smad1/5/8
To investigate the effect of forced expression of Eng cells
were treated with BMP4 after 24 h of transfection with the
Eng expression vector and probed for levels of phospho-
Smad1/5/8 24 h after BMP4 treatment. Forced Eng expres-
sion enhanced the BMP4-induced increase in phospho-
Smad1/5/8 levels (Fig. 4D).
Discussion
IHH and BMP4 are the only factors that have been reported
to be sufficient for EC specification from ESC (Iacobas
et al., 2010; Kelly and Hirschi, 2009). While these factors
alone or in combination with late acting factors such as
VEGF have been shown to induce EC differentiation from
ESC (Nourse et al., 2010; Pearson et al., 2008), thedifferentiation has been found to be inefficient (Iacobas et
al., 2010). Because of this inefficiency, production of suffi-
cient EC for experimentation has required sorting and sub-
culture. However, while changes in cell properties as a
result of culturing and passaging the cells are not fully un-
derstood, it is well established that cell culture induces epi-
genetic changes (Maitra et al., 2005; Kim et al., 2007) that
may affect cell properties. Identifying new EC specification
genes that may increase the efficiency of EC differentiation
is an important contribution to the field of regenerative
medicine.
Soluble growth factors are commonly used to induce cellu-
lar differentiation from ESC. Indeed, BMP4 and VEGF have not
only been shown to be synergistic in inducing ESC differentia-
tion into EC (Nakayama et al., 2000; Bai et al., 2008) but also
to represent the optimum combination for the differentiation
(Pearson et al., 2008). Because at optimal concentration,
BMP4 may induce the expression of VEGF or other VEGF family
members (Tokuda et al., 2003), BMP4 may be able to complete
the EC differentiation program. BMP4 treatment may repre-
sent the optimumEC differentiation treatment reported so far.
In the present study, we showed for the first time, that
recombinant Eng is at least as efficient in EC specification
as BMP4 (Figs. 1B–G and 3A), highlighting the contribution
of this study in endothelial differentiation. Moreover, we
found that recombinant Eng enhances the BMP4-induced EC
differentiation (Figs. 1B–G, 3A), further highlighting the
contribution of this study. Eng has been found to exist in
both a membrane-bound receptor form and a soluble form
in both normal and pathological conditions (Levine et al.,
2006; Venkatesha et al., 2006; Wang et al., 1994). Physiolog-
ically, recombinant Eng mimics the soluble form of Eng.
To further define the role of Eng in EC specification under
physiological conditions, we forced the expression of Eng in
mouse ESC. Previous studies (Lebrin and Mummery, 2008)
have established that forced expression of membrane-bound
receptors results in active membrane-positioned receptors.
We found that forced Eng expression resulted in expression of
both the membrane-bound and the soluble forms of Eng
(Fig. 2B). Like with the recombinant Eng experiments, forced
Eng expression induced EC differentiation as robust as with
BMP4 treatment and the effect of BMP4 on EC differentiation
was enhanced by forced Eng expression (Figs. 2D–I and 3B–C).
During gastrulation, posterior epiblast cells migrate
through the primitive streak to form the mesoderm. Several
signals cooperate to promote vascular mesoderm specifica-
tion during gastrulation. BMP4, whose expression prior to
gastrulation is localized to the primitive streak, is one of
the factors that have been shown to be required for mesen-
dodermal specification, but other factors such as TGF family
members (activin A), Wnt family members (Wnt3a) have
been implicated. Commitment of multipotent mesendoder-
mal cells to the endothelial cell lineage is thought to be reg-
ulated by soluble signals derived from adjacent endodermal
cells. To determine whether Eng acts at the level of mesen-
dodermal or vascular mesoderm specification or even at a
later stage, we determined its effect on the expression of
mesoderm markers during the early stage of ESC differentia-
tion. Fig. 2C indicates that BMP4 treatment increases the ex-
pression of the primitive streak/mesendoderm and early
mesoderm markers brachyury (Kispert and Herrmann, 1994)
and Wnt3 (Liu et al., 1999). The effect of BMP4 on the
90 S. Banerjee et al.expression of the mesendoderm/mesoderm markers de-
clined with time but the BMP4 effect was sustained by forced
Eng expression. Forced Eng expression had no effect on
mesendoderm/mesoderm formation in absence of BMP4
(Fig. 2C), suggesting that Eng may not exert its effects in
early stages of ESC differentiation, but may direct primitiveFigure 2 Forced Eng expression has no effect on expression of mes
the stimulatory effect of BMP4. In addition, it increases the numbe
duced increase in this cell population. Embryonic stem cells were t
in Materials and methods. (A). Quantitative PCR analysis of Eng ex
was normalized over Gapdh expression. (B). Immunocytochemical a
sion of Eng is shown in green (Alexa Fluor 488) and nuclei were cou
expression of the mesoderm markers brachyury and Wnt3 in d
(100 ng/mL) and forced Eng expression. Brachyury and Wnt3 expres
cytochemical analysis of VE-cadherin- and vWF-positive cells. VE-cad
formed six days after BMP4 treatment (100 ng/mL) and forced Eng
were acquired using Olympus IX71 Inverted Microscope with Olym
Flow cytometric analysis of the number of cells expressing the endo
BMP4 treatment (100 ng/mL). Flow cytometry was performed using
FlowJo7.6 software. (F). Representative plots of Tie2 positive cells
cells expressing Tie2 from the flow cytometry data. (H, I) Flow cytom
plots of CD 31 and Tie2 double positive cells. (I). Quantitative and s
CD31 and Tie2 from the flow cytometry data. Data are representat
value≤0.01 and 0.05, respectively. NS: statistically non-significantstreak mesendodermal precursors formed under the influ-
ence of BMP4 towards vascular mesoderm and EC.
The EC marker gene-expressing cells resulting from Eng
treatmentwere functional EC as determined by their angiogen-
esis potential (Fig. 3A–B) and their ability to express Icam-1
in response to TNF-α treatment (Fig. 3C), a characteristic ofodermal markers in absence of BMP4, but enhances and prolongs
r of cells expressing the EC markers and enhances the BMP4-in-
ransfected with a plasmid expressing the Eng ORF as described
pression after 24 and 48 h of Eng transfection. Eng expression
nalysis of Eng expression after 24 h of transfection. The expres-
nter-stained with DAPI (blue). (C). Quantitative PCR analysis of
ifferentiating ESC 24, 48, and 72 h after BMP4 treatment
sions are normalized over 18s rRNA expression. (D, E). Immuno-
herin (D) and vWF (E) staining (green, Alexa Fluor 488) was per-
expression. Nuclei were counter-stained by DAPI (blue). Images
pus micro DP 70 software. The magnification was ×200. (F–I)
thelial cell markers after six days of forced Eng expression and
the FACSCalibur flow cytometer and data were analyzed using
. (G) Quantitative and statistical analysis of the percentage of
etric analysis of CD31+ Tie2+ cells. (H). Representative scatter
tatistical analysis of the percentage of cells double positive for
ive of at least three different experiments. ** and * indicate p
. Ev: empty vector.
Figure 2 (continued).
91Eng is a novel EC specification genemature EC commonly used to determine the functionality of EC
(Nourse et al., 2010).We previously reported that in our hands,
the angiogenic potential of mouse EC is not as good as that of
HUVECs (Banerjee and Bacanamwo, 2010). This explains whythough recombinant Eng and BMP4 or their combination in-
creased the formation of the vascular-like network, the net-
works are not fully formed (Fig. 3A). Similarly, the vascular-
like network induced by forced Eng expression was even less
Figure 3 Eng induces mouse ESC to differentiate into functional EC. Angiogenesis assay of differentiating ESC treated for six days
with BMP4 (100 ng/mL) and recombinant Eng (700 ng/mL) (A) or with BMP4 (100 ng/mL) and the Eng ORF (B). The representative im-
ages were taken 6 h after the beginning of the angiogenesis assay. (C) Quantitative PCR analysis of Icam1 expression in response to
TNF-α treatment for 4 h in differentiating ESC after six days of BMP4 treatment (100 ng/mL) and forced Eng expression. Icam1 expres-
sion is normalized over Gapdh expression. Data are representative of at least three different experiments. **Indicates p value≤0.01.
Ev: empty vector.
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Figure 4 Eng effects are not mediated by either Ihh or Bmp4 and are independent of BMP4 signaling. Quantitative PCR analysis of
Ihh (A) and Bmp4 (B) expressions in differentiating ESC after 24, 48, and 72 h of forced Eng expression. (C, D). Western blot analysis
and densitometric quantification of levels of phospho-Smad1/5/8 in differentiating ESC after 24 h of treatment with BMP4
(100 ng/mL) and recombinant Eng (700 ng/mL) (C) or with BMP4 (100 ng/mL) and the Eng ORF (D). Data are representative of at
least three different experiments. *Indicates p value≤0.05. NS: statistically non-significant. Ev: empty vector.
93Eng is a novel EC specification geneformed (Fig. 3B). However, Icam-1 expression response to
TNF-α treatment, another measure of EC function, did show
a significant effect of forced Eng expression (Fig. 3C). McClos-
key et al. (2006) reported that VE-cadherin in the ESC-derived
EC did not localize as well at the cell–cell junctions as in the
mature endothelial cells. However, in the Eng-induced differ-
entiation (both recombinant and forced expression Eng), VE-
cadherin did correctly localize in cell–cell junctions (Figs. 1B,2D), a feature characteristic of mature functional endothelial
cells.
To determine the molecular mechanisms mediating the
Eng effects on EC specification, we investigated the effect
of Eng on the expression of the two signaling molecules
known to be sufficient for EC specification, IHH and BMP4
(Kelly and Hirschi, 2009). As indicated in Fig. 4A and B, Eng
does not have any significant effect on the expression of
94 S. Banerjee et al.Ihh or Bmp4 by up to 3d of treatment, suggesting that Eng is
a novel EC specification gene, acting through a pathway dif-
ferent from that of the known EC specification genes. This
may also explain the synergy between Eng and BMP4 in EC
differentiation (Figs. 1B–G, 2D–I, and 3A–C). Because the
effect of IHH is mediated by BMP4 (Kelly and Hirschi,
2009), Eng–BMP4 treatment combination may represent
the minimum yet optimum cocktail for EC specification.
Previous studies showed that short-term BMP4 treatment
followed by treatment with BMP4 antagonists promoted meso-
derm induction and EC specification (Zhang et al., 2008). Eng
has been reported tomediate and regulate TGF-β and BMP4 sig-
naling in a context-dependent manner, acting as an inducer of
TGF-β/BMP4 signaling or an inhibitor, or independent of
TGF-β/BMP4 signaling (reviewed by Lebrin and Mummery,
2008). To determine whether though Eng does not induce
BMP4 expression it may enhance the BMP4-induced EC specifi-
cation by modulating BMP4 signaling, we determined the effect
of Eng on the BMP4-induced increase in phospho-Smad1/5/8
levels. While recombinant Eng antagonized BMP4 signaling
(Fig. 4C), forced Eng expression enhanced BMP4 signaling
(Fig. 4D). In endothelial cells, the soluble form of Eng competes
with other ligands such as TGF-β and potentially BMP4 for bind-
ing to their cognate receptors (Venkatesha et al., 2006). This
may explain why the recombinant soluble Eng form antagonized
BMP4 signaling. Conversely, given that membrane-bound Eng is
a co-receptor for the TGF-β family of ligands, it can be argued
that increasing levels of membrane-bound Eng increases BMP4
receptor activity and downstream signaling through Smad phos-
phorylation. After forced Eng expression, Eng appears mostly in
the bound, receptor form (Fig. 2B). This increased receptor ac-
tivity as a result of Eng forced expression may explain the in-
creased BMP4 signaling following the forced Eng expression.
However, both recombinant Eng and forced Eng expression en-
hanced the BMP4-induced EC specification, suggesting that
the effect of Eng on EC specification is not mediated by BMP4
signaling. Recombinant Eng inhibited the pro-proliferative
Smad1/5/8 pathway while forced Eng expression enhanced it,
yet both resulted in increased EC formation. This suggests that
the increased EC in differentiating ESC treated by Eng cannot
be explained by the pro-proliferative and pro-survival effects
of Eng (Lebrin et al., 2004). However, though Eng alone had
no significant effects on mesodermal differentiation (Fig. 2C),
Eng appeared to prolong and enhance the activating effect of
BMP4 on expression of the mesoderm markers brachyury and
Wnt3 (Fig. 2C). This may explain the enhancing effects of Eng
on the BMP4-induced EC specification.
Our finding that Eng plays a significant role in the EC
specification is consistent with the published data that
support a role of Eng in vascular development (ten Dijke
and Arthur, 2007) and angiogenesis (ten Dijke et al.,
2008). It is also consistent with the recent finding that
ERG1 induces Eng expression and the differentiation of
ESC into EC (Nikolova-Krstevski et al., 2009). Future stud-
ies should establish whether Eng is a mediator of the
ERG1-induced EC differentiation.Conclusions
We have identified Eng as a novel EC specification gene which
acts independently of the major known EC specificationgenes. It is synergistic to the BMP4-induced EC differentiation,
resulting in a robust EC differentiation from ESC. More studies
are needed to further elucidate the mechanisms underlying
the Eng-induced EC specification. We have shown previously
that manipulation of the stem cell epigenome by pharmacolog-
ical inhibition of DNA methyltransferases induces the ESC and
bone marrow-derived adult stem cell differentiation into the
EC lineage much more efficiently than the various growth fac-
tors (Banerjee and Bacanamwo, 2010; Mahpatra et al., 2010).
This was associated with increased expression of Eng, suggest-
ing that Engmay be a centralmediator of the DNAmethyltrans-
ferase (DNMT)-inhibition-induced EC differentiation. We are
evaluating this hypothesis.
Materials and methods
Cell culture and differentiation
Mouse ESC line J1 was a gift from Dr. En Li (Novartis Institute
for BioMedical Research, Emeryville, CA). ESC were grown
and routinely maintained in PluristemTM 129S6 cell media
(Millipore, Billerica, MA) in feeder free media as described
previously (Banerjee and Bacanamwo, 2010). To study the
effect of Eng, about 2.0×105 ESC were plated overnight on
gelatin-coated 6-well plates and then treated either with a
full length recombinant Eng (700 ng/mL) (Abnova, Taiwan)
or transfected with full length Eng cDNA construct (Origene
Technologies, Rockville, MD). Cells were then differentiated
in presence or absence of recombinant BMP4 (100 ng/mL) in
differentiation media (Pluristem™ 129S6 cell media) without
leukemia inhibitory factor (LIF) in adherent culture for three
days. This BMP4 dose is routinely used in BMP4-mediated EC
specification studies (Boyd et al., 2007). After three days,
cells were washed with PBS and differentiated up to seven
days in differentiation media in adherent culture without
any supplement. Mouse brain endothelial cells (mBEC)
were purchased from ATCC (Manassas, VA) and used in the
experiments as EC controls.
Forced Eng expression in differentiating ESC
An expression vector expressing the mouse Eng cDNA was
purchased from Origene Technologies (Rockville, MD) and
used in the forced Eng expression experiments. The vector
was digested with NotI and KpnI restriction enzymes (New
England Biolabs, Ipswich, MA) to remove the Eng cDNA,
blunted, self-ligated, and used as the empty vector control.
ESC plated overnight in 6-well tissue culture plates were
transfected with 2 μg of Eng or empty vector using Attrac-
tene Transfection Reagent (Qiagen, Valencia, CA) following
manufacturer's protocol.
Quantitative RT-PCR analysis
Total cellular RNA was extracted using the RNeasy mini kit (Qia-
gen, Valencia, California). cDNA was synthesized using the
iScript cDNA synthesis kit (BioRad, Hercules, CA). The expres-
sion of Ihh, Bmp4, Eng, Icam1, brachyury, Wnt3a, and 18s
rRNA was quantified by real-time PCR analysis using Roche
light cycler 480 and Lightcycler 480 SYBR Green I master assay
kit (Roche, Indianapolis, IN). mRNA expression is normalized
95Eng is a novel EC specification geneover Gapdh or 18s rRNA expression. PCR primers were designed
with the Invitrogen's OligoPerfect™ Designer software and the
following primer sequences were used: Ihh (forward 5′-
CGTGCATTGCTCTGTCAA GT-3′ and reverse 5′-CTCGATGACCT
GGAAAGCTC-3′); Bmp4 (forward 5′-CCTGGAC ACCTCATCACAC-
GAC-3′ and reverse 5′-GGCGACGG CAGTTCTTATTCTT-3′); Eng
(forward 5′-CTTCCAAGGACAGCCAAGAG-3′ and reverse 5′-
GTGGTTGCCATTCAAGTG TG-3′); Icam1 (forward 5′-
AGCACCTCCCCACCTACTTT-3′ and reverse 5′-AGCTTGCACG
ACCCTTCTAA-3′); brachyury (forward 5′-CCGGTGCTGAAGG-
TAAATGT-3′ and reverse 5′-CCTCCATTG AGCTTGTTGGT-3′);
Wnt3 (forward 5′-CCGCTTCTGTCTAGGGTCTG-3′ and reverse
5′-GGTAGAGAGTGCAGGCAAGG-3′); 18s rRNA (forward 5′-
GGAAGGGCACCACCAGGAGT-3′ and reverse 5′-TGCAGCCCCG-
GACATCTAAG-3′).
Western blotting
Total proteins were extracted using the phosphosafe lysis
buffer (Novagen, Madison, WI) and sonication performed at
3 W for 15 s using a VirSonic 100 VirTis Sonicator (Gardiner,
NY). About 30–50 μg proteins were electrophoresed on 4–
20% SDS-PAGE (BioRad, Hercules, CA). Proteins were trans-
ferred to a nitrocellulose membrane and blocked with 5%
BSA in TBS-Tween-20 (0.05% Tween-20) and incubated with
anti-brachyury (1 μg/mL) (Abcam, Cambridge, MA), anti-
phospho-Smad1/5/8 (1:1000) (Cell Signaling, Danvers, MA) or
anti-β-actin (1:1000) (Santa Cruz Biotechnology, Santa Cruz,
CA) antibodies. After washing, the blots were incubated for
1 h with horseradish peroxidase-conjugated anti-rabbit or
anti-mouse IgG antibody (1:2000, Invitrogen, San Diego, CA)
and visualized by enhanced chemiluminescence.
Immunocytochemistry
Cells grown in 6-well plates were fixed with 4% paraformal-
dehyde and were stained for VE-cadherin (BD Biosciences,
San Jose, CA), Eng (Abcam, Cambridge, MA), or for vWF
(Santa Cruz Biotechnology, Santa Cruz, CA) following the
protocol described earlier (Banerjee and Bacanamwo,
2010).
Flow cytometry
Differentiated cells were permeabilized with methanol,
washed with PBS and blocked in 5% BSA and stained with
Tie2 antibody or its isotype control (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) for an hour at room temperature.
After washing, cells were incubated with anti-rabbit-IgG-
Alexa Fluor 488 antibody for an hour, washed with PBS,
and resuspended in 2% paraformaldehyde. We used the in-
tracellular epitope antibody for Tie2 from Santa Cruz and
intracellular FACS analysis as used by others (Asahara et
al., 1997; Liu et al., 2005; Liu et al., 2009) because at-
tempts to use cell surface epitope antibodies were unsuc-
cessful. For CD31 and Tie2 double staining, cells were
stained with PE-conjugated CD31 (BD Biosciences, San
Jose, CA) or the corresponding isotype control for an hour
at room temperature. After washing with PBS, cells were
stained for Tie2 as described above, then FACS was per-
formed using FACSCalibur cytometer (BD Biosciences, SanJose, CA). 20,000 events were acquired at each run and
the data were analyzed using FlowJo7.6 (Treestar, Ash-
land, Oregon). Due to the heterogeneous population of
cells in different treatment groups, gates in each treat-
ment group were set based on the signal of the isotype
control.
Angiogenesis assay
0.2 mL of Matrigel from angiogenesis assay kit (Millipore, Bill-
arica, MA) was added to 24-well plates and allowed to solidify
at 37 °C for 1 h. Cells from different treatment groups were
serum-starved (grown on 0.4% serum) for 16 h, plated at a
density of 50,000 to 100,000 per well and incubated at 37 °C
in mouse endothelial cell culture media and observed at dif-
ferent time intervals. mBEC were used as positive controls.
Assay for TNFα-inducible Icam-1 expression
TNF-α induced expression of Icam-1 is a characteristic of EC
and has been used to assay the functionality of differentiated
EC (Nourse et al., 2010). Differentiated cells were serum-
starved (grown on 0.4% serum) for 16 h and stimulated with
10 ng/mL of TNF-α for 4 h. Icam-1 expression was quantified
using quantitative real time PCR. Values are normalized over
Gapdh expression.
Statistical analysis
Data on the effect of treatment on mRNA expression and %
of cells expressing Tie2 was analyzed by pair-wise t-test.
p Values≤0.05 were considered to be statistically signifi-
cant. Unless otherwise specified, the data is presented as
mean± standard error of the mean.
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